Ligand Pharmaceuticals Reports Higher Year-Over-Year Profit on Every Reported Earnings Line, With a Loss-to-Profit Transition in the Six-Month Window

Bottom line

- The earnings release for LIGAND PHARMACEUTICALS INC (ticker LGND), filed under accession 0000886163-26-000044 as the 10-Q for period-ended-2026-06-30, reports profit on every reported earnings line for both the three-month reporting period (the three months ended June 30, 2026) and the six-month year-to-date period (the six months ended June 30, 2026), with year-over-year increases in earnings per share, net income attributable to parent, operating income, and revenue.

- Revenue from Contract with Customer, Excluding Assessed Tax was higher than the prior year for the three-month reporting period (current $63,693,000 USD versus prior-year $47,627,000 USD) and for the six-month year-to-date period (current $115,415,000 USD versus prior-year $92,960,000 USD).

- Net Income (Loss) Attributable to Parent for the three-month reporting period was higher than the prior year (current $48,508,000 USD versus prior-year $4,847,000 USD). For the six-month year-to-date period, the result moved from a loss in the prior year (-$37,604,000 USD) to a profit in the current period ($35,163,000 USD).

- Operating Income (Loss) for the three-month reporting period was higher than the prior year (current $8,591,000 USD versus prior-year $8,444,000 USD). For the six-month year-to-date period, the result moved from a loss in the prior year (-$27,772,000 USD) to a profit in the current period ($25,959,000 USD).

- Earnings Per Share, Diluted for the three-month reporting period was higher than the prior year (current $2.22 per diluted share USD/SHARES versus prior-year $0.24 per diluted share USD/SHARES). For the six-month year-to-date period, the result moved from a loss in the prior year (-$1.95 per diluted share USD/SHARES) to a profit in the current period ($1.63 per diluted share USD/SHARES).

- Management describes the Company as a biopharmaceutical royalty business focused on deploying capital and licensing technologies to acquire and create diversified royalty streams from high-value medicines, with capital deployment and technology licensing identified as the primary drivers of long-term growth. The Company reports a single operating and reportable segment.

- The cautionary statement directs readers to risk factors disclosed in the filing, specifically the risk-factor item referenced as Item 1A under the caption "Risk Factors," which could negatively affect results of operations, financial condition, and trading price.

- Source scope for this analysis is the unaudited condensed consolidated financial statements and accompanying notes filed with this 10-Q, together with the cautionary note regarding forward-looking statements. The filing evidence does not provide peer or industry comparison data, and the filing evidence does not attribute any of the reported year-over-year changes to a single cause.

Financial performance

- The reported revenue line is materially higher than the prior-year comparative in both the three-month reporting period and the six-month year-to-date period, consistent with the company's description of a royalty-driven model where royalty receipts scale with partner product sales and Captisol material sales, supplemented by license fees and milestones. The narrative frames this revenue as primarily royalties on partner sales, with the cited accounting policy making clear that sales-based royalties are constrained to the quarter in which the underlying sale occurs.

- Operating income (loss) shows a loss-to-profit transition in the six-month year-to-date period against the prior-year comparative, and a profit-to-profit result with an authorized increase in the three-month reporting period against its prior-year comparative. Net income (loss) attributable to parent follows the same shape: a loss-to-profit transition year-to-date and a higher profit in the quarter. Earnings per share, diluted mirrors that pattern, with the six-month period moving from a loss per share to a profit per share and the three-month period showing a higher profit per share than the prior year quarter.

- The accounting context the filing offers is concentrated in two areas. First, the basis-of-presentation note states that interim results are not necessarily indicative of the full year and that figures should be read alongside the audited consolidated financial statements in the cited Annual Report. Second, the revenue policy note describes the five-step model under the cited revenue recognition standard, with an explicit royalty-constraint clause that defers sales-based royalty revenue to the period of the underlying sale — a structural feature relevant when quarter-to-quarter volatility is being interpreted.

- Segment information is presented as a single operating and reportable segment, with the cited Chief Operating Decision Maker evaluating performance using net income (loss) and segment operating income (loss) rather than segment asset measures. The "Other" category in segment reporting is described as capturing residual general, administrative, research and development expenses net of share-based compensation and depreciation, plus fair-value adjustments to partner program derivatives, Captisol costs, and other non-operating items — a useful pointer to where non-recurring mark-to-fair-value movements are surfaced.

- The filing does not provide quantitative guidance ranges for upcoming periods, and the cautionary language in the cited risk-factor cross-reference signals that forward-looking statements speak only as of the report date. The filing evidence does not attribute this change to any single cause. - No peer or industry comparison is contained in the filing evidence.

The filing evidence contains no peer or industry comparison. - Across the reported profitability dimensions, every year-to-date line shows an authorized loss-to-profit transition and every quarterly line shows an authorized profit-on-profit increase, which is a uniformly favorable comparison set rather than a mixed one; readers comparing this shape with peers who report narrower or partial improvements, such as Atlantic Union Bankshares posts higher year-over-year profit on every reported earnings line for both the three-month reporting period and the six-month year-to-date period, should weigh that the underlying revenue drivers here are royalty receipts and Captisol sales rather than net interest income.

Operating drivers and segments

Ligand reports a single operating and reportable segment centered on investing in the clinical development and commercialization of high-value medicines, and the filing does not present separate pharmaceutical, technology-licensing, or royalty-stream segment results that would allow comparison of segment-specific margins.

Revenue moved higher year over year in both reporting windows. The three-month revenue was $63,693,000 for the three months ended June 30, 2026, versus $47,627,000 for the three months ended June 30, 2025. The year-to-date revenue was $115,415,000 for the six months ended June 30, 2026, versus $92,960,000 for the six months ended June 30, 2025.

Operating income also improved on the reported comparisons. Operating income was $8,591,000 for the three months ended June 30, 2026, compared with $8,444,000 for the three months ended June 30, 2025. In the year-to-date period, operating income was $25,959,000 for the six months ended June 30, 2026, compared with an operating loss of -$27,772,000 for the six months ended June 30, 2025, a transition from loss to profit. Because only consolidated figures are supplied, the evidence does not establish how much of the margin improvement came from any individual revenue category, investment, licensing activity, or cost line.

The segment profit measure used by management is net income or loss, while internal management reporting also provides segment operating income or loss for financial decisions and resource allocation. The chief operating decision maker does not evaluate, manage, or measure segment performance using asset information, which limits the usefulness of the segment disclosure for independently analyzing returns on deployed capital. Management describes the business as a biopharmaceutical royalty company that deploys capital and licenses technologies to acquire and create diversified royalty streams from high-value medicines. It identifies capital deployment and technology licensing as the primary drivers of long-term growth and portrays the corporate structure as lean, with the intended benefit of supporting long-duration, non-dilutive cash flows. Risk factors referenced under Item 1A are identified as capable of negatively affecting results of operations, financial condition, and the trading price of the stock, which is relevant when interpreting management’s growth language: the reported revenue and operating-income improvements are observable, but the filing does not provide a detailed bridge showing which operating activities produced the changes.

The filing evidence does not attribute this change to any single cause.

Independent analysis can confirm the direction of the reported revenue and operating-income comparisons, but it cannot isolate segment-level margins or attribute the improvement to a particular business driver from the filing evidence. The filing evidence contains no peer or industry comparison.

Management’s forward-looking statements are expressly based on facts and factors currently known to it and remain subject to risks and uncertainties, so expectations concerning future royalties, milestones, product development, regulatory matters, or growth should be treated as management claims rather than verified operating drivers.

Cash flow and capital

The six-month year-to-date period showed a meaningful shift in cash-generation profile relative to the prior-year comparative. Net Cash Provided by (Used in) Operating Activities moved from a negative figure in the prior-year window to a clearly positive figure in the current six-month window — a swing from cash absorption to cash generation at the operating line. Net Cash Provided by (Used in) Investing Activities likewise improved, moving from a negative prior-year comparative to a positive reading in the current period. Net Cash Provided by (Used in) Financing Activities increased year over year but remained positive in both windows, leaving the financing stream as a continuing source of cash inflow rather than a use of cash.

On the investing side, Payments to Acquire Property, Plant, and Equipment decreased relative to the prior-year comparative, which is consistent with a capital-light partner model that the company describes as avoiding high-cost infrastructure of its own. Payments for Repurchase of Common Stock rose from effectively zero in the prior-year window to a positive amount in the current six-month window, indicating an active return-of-capital program this period that did not exist to a meaningful extent a year earlier. No commentary in the quoted narrative ties these movements to specific drivers, so the cause of either the lower capital spending or the resumed repurchase activity The filing evidence does not attribute this change to any single cause..

On the balance sheet at the period-end date, the company reported a positive Cash and Cash Equivalents balance alongside positive Accounts Receivable, after Allowance for Credit Loss, and positive Accounts Payable balances, each presented in the standard current-asset and current-liability format. The relationship among these three balances suggests a working-capital posture in which receivables and payables coexist with a meaningful cash position — a shape consistent with the operating-cash inflow recorded for the period, though the quoted evidence does not compute a working-capital ratio or any quantitative metric for us to cite.

Capital allocation across the six-month window therefore combined three observable behaviors: lower property, plant, and equipment outlays than the prior year, a return-of-capital program in the form of share repurchases that was effectively absent a year ago, and an operating cash flow that flipped to positive. Investing activities also turned positive, which combined with lower capital expenditures implies the company is funding its capital-return program without leaning entirely on operations — though, again, the source narrative does not explicitly walk through that arithmetic, so any further attribution The filing evidence does not attribute this change to any single cause..

For readers who want to model the resulting cash position alongside other earnings-line examples, the Atlantic Union Bankshares posts higher year-over-year profit on every reported earnings line for both the three-month reporting period and the six-month year-to-date period insight provides a useful cross-reference for how a return-of-capital story can interact with an improving earnings line.

Segment-level detail across the cash flow and balance sheet lines is not disclosed in the quoted evidence, so any breakdown by royalty asset class, Captisol, or partner The filing evidence does not disclose segment-level detail for this dimension., and the filing evidence contains no peer or industry comparison The filing evidence contains no peer or industry comparison..

Peer and historical context

- Across both the three-month reporting period and the six-month year-to-date period, top-line, operating, and bottom-line lines printed profit in the current window, leaving the year-ago window more mixed. - The most striking historical shift sits on the year-to-date book, where revenue was already positive in the prior year, but net income and operating income moved from a loss to a profit — a clean loss-to-profit transition on the parent line and on the operating line over the same six-month comparison. - The quarterly comparison is more measured: revenue, operating income, and net income were positive in both the current quarter and the prior-year quarter, so the directional story for the three-month window is simply higher profit on each line rather than a swing in sign.

- Operating cash flow over the six months flipped from a use of cash in the prior year to a source of cash in the current year, which is the cleanest change-of-sign in the cash-flow set and lines up directionally with the year-to-date earnings flip. - The reported improvement does not extend uniformly to every line: revenue direction was already positive year-over-year in the prior comparison, so the headline revenue gain in the six-month window is a continuation rather than a turn, and the loss-to-profit narrative applies only to the operating and net-income lines, not to revenue.

- Even on the lines that did flip from loss to profit, the qualitative direction is set, but the size of the swing — how wide the prior-year loss was versus how wide the current profit is — cannot be read off the cataloged facts, so framing this as a "sharp" or "modest" recovery would be speculation rather than analysis. - For a like-for-like peer read, the filing evidence contains no comparable company set, no industry index, and no consensus figure; the cross-sectional context has to be treated as absent rather than inferred.

The filing evidence contains no peer or industry comparison. - Segment-level contribution to the year-to-date operating swing is also absent from the evidence base, so attributing the loss-to-profit move to Captisol, royalties, or contract revenue individually would overstate what the filing discloses. The filing evidence does not disclose segment-level detail for this dimension.

- Cause language is deliberately omitted for the same reason: the filing narrative describes revenue-recognition mechanics for royalties, Captisol, and contract revenue but does not tie any single driver to the year-over-year improvement, so the change is recorded without a stated cause. The filing evidence does not attribute this change to any single cause. - Readers who want a parallel pattern of a higher year-over-year profit on every reported earnings line can compare the directional shape of this filing with Atlantic Union Bankshares posts higher year-over-year profit on every reported earnings line for both the three-month reporting period and the six-month year-to-date period, noting that the two stories share a "higher on every line" pattern in the quarter while differing on the year-to-date book, where Ligand additionally carries a loss-to-profit transition.

Scenario analysis

- The reported revenue and net income lines carry the directional momentum implied by the year-over-year comparatives in 10-Q period-ended-2026-06-30 (accession 0000886163-26-000044): both periods show higher revenue than the prior year, and the parent net income line moved from a loss to a profit on the year-to-date basis while holding at a profit on the quarterly basis.

- Supporting reported values for the base case: - Three-month revenue: $63,693,000 for the three months ended June 30, 2026, against $47,627,000 for the three months ended June 30, 2025; higher than the prior-year window. - Six-month revenue: $115,415,000 for the six months ended June 30, 2026, against $92,960,000 for the six months ended June 30, 2025; higher than the prior-year window. - Three-month net income: $48,508,000 for the three months ended June 30, 2026, against $4,847,000 for the three months ended June 30, 2025; a profit in both windows with the current period higher. - Six-month net income: $35,163,000 for the six months ended June 30, 2026, against -$37,604,000 for the six months ended June 30, 2025; a profit versus a prior-year loss, a loss-to-profit transition.

- Management-stated context anchors the base case to existing Captisol and intellectual-property licensing arrangements and to milestone- or royalty-style variable consideration that is recognized when contingencies are probable. That posture is consistent with the reported revenue direction without implying any specific forecast.

- Sustained receipt of contract revenue and contingent milestone payments under existing licensing and Captisol arrangements, paired with operating leverage from the operating-income transition observed in the year-to-date comparatives (profit now versus a loss in the prior-year window). - Persistence of the year-to-date revenue growth reported for the six months ended June 30, 2026 versus the six months ended June 30, 2025 and the quarterly revenue growth reported for the three months ended June 30, 2026 versus the three months ended June 30, 2025, alongside the year-to-date net-income improvement from -$37,604,000 to $35,163,000. - Allowance for credit losses held roughly flat against current receivables aging, consistent with the loss-rate methodology referenced in the cited note.

- Reversal of the year-over-year revenue improvement reported for both windows if contingent milestone payments or royalties do not clear the probability threshold, given the reliance on license-related variable consideration. - Renewed credit-loss provisions if macroeconomic and aging inputs shift adversely, since the methodology explicitly draws on those factors; reported allowance increases during both reported windows illustrate the sensitivity. - Execution or regulatory risk on partner programs that drive milestone economics, as framed under Item 1 and Item 1A in the Risk Factors discussion, which could compress the year-to-date profitability transition documented between the six months ended June 30, 2026 and the six months ended June 30, 2025.

Risks and what to watch

- The standalone risk overlay is framed by Item 1 and Item 1A of 10-Q (period-ended-2026-06-30, filed under 0000886163-26-000044 for LIGAND PHARMACEUTICALS INC, ticker LGND), which both caution that items under the "Risk Factors" caption could negatively affect results. The headline pattern is consistent with that caution: a six-month swing on the parent line and a continued profit posture on the quarterly line, with several specific counter-signals embedded in the notes. - Net Income (Loss) Attributable to Parent moved from a prior-year loss of -$37,604,000 USD over the six-month comparative to a current six-month profit of $35,163,000 USD, a loss-to-profit transition.

The quarter line stayed profitable in both years, comparing $4,847,000 USD with $48,508,000 USD, so the wider swing is concentrated in the year-to-date window rather than the most recent three months. The filing evidence does not attribute this change to any single cause. - Revenue from Contract with Customer, Excluding Assessed Tax was higher than the prior-year comparative in both reporting windows.

The three-month line moved from $47,627,000 USD to $63,693,000 USD, and the six-month line moved from $92,960,000 USD to $115,415,000 USD, so the top-line direction is consistent across periods. The filing evidence does not attribute this change to any single cause. - Counter-evidence sits in the credit-quality disclosures of Note 1.

Management increased the allowance for credit losses during the recent quarter and during the six-month period, citing current and expected future economic and market conditions, and the same note limits the credit-loss recognition on available-for-sale debt securities to the carrying-value-over-fair-value gap. No credit losses were recognized in either window, but the allowance was still topped up, which is a quieter form of counter-evidence to the broader profit narrative. The unrealized losses on debt securities are attributed by management to interest-rate changes rather than to credit deterioration, which is a separate but related piece of counter-evidence.

- Unrecognized contractual exposure is flagged in Note 8. Some customer contracts are sublicenses that require payments to an upstream licensor tied to the license fees, milestones, and royalties that LIGAND PHARMACEUTICALS INC receives from customers, and the same area discusses contingent milestone and royalty income whose recognition depends on development and regulatory events that may never occur. Note 6 adds the share-based compensation and unrealized-gain/loss texture that shapes the wider operating result.

These disclosures are the parts of the catalog that an investor cannot yet quantify, which is why they belong in the watch list rather than in the headline. - Peer and industry context for these movements is not in the filing evidence. The filing evidence contains no peer or industry comparison.

- Metrics to watch next period: the trajectory of Revenue from Contract with Customer, Excluding Assessed Tax in the next three-month and six-month windows; whether the parent line stays profitable in both periods; any change in the allowance for credit losses; the fair-value gap on available-for-sale debt securities; and any new contingent milestone or royalty event under Note 8. A reader checking year-over-year direction across multiple issuers can cross-reference Atlantic Union Bankshares posts higher year-over-year profit on every reported earnings line for both the three-month reporting period and the six-month year-to-date period to see how a peer set frames the same direction.